Concentration-dependent mortality of chloroquine in overdose

James A Watson[1,2]*, **Joel Tarning**[1,2], **Richard M Hoglund**[1,2], **Frederic J Baud**[3,4],
Bruno Mégarbane[5,6], **Jean-Luc Clemessy**[3,6], **Nicholas J White**[1,2]

*For correspondence:
jwatowatson@gmail.com (JAW)

[1]Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine,
Mahidol University, Thailand; [2]Centre for Tropical Medicine and Global Health, Nuffield
Department of Medicine, University of Oxford, United Kingdom ; [3]Assistance Publique -
Hôpitaux de Paris, Paris, France; [4]Université de Paris, Paris, France; [5]Université de Paris,
INSERM UMRS-11 44, F-75006, Paris, France; [6]Réanimation Médicale et Toxicologique,
AP-HP, Hôpital Lariboisiére, F-75010 Paris, France; [7]Clinique du Sport, Paris, France

Abstract Hydroxychloroquine and chloroquine are used extensively in malaria and
rheumatological conditions, and now in COVID-19 prevention and treatment. Although generally
safe they are potentially lethal in overdose. *In-vitro* data suggest that high concentrations and
thus high doses are needed for COVID-19 infections, but as yet there is no convincing evidence
they are clinically effective. Bayesian regression models were fitted to survival outcomes and
electrocardiograph QRS durations from 302 prospectively studied French patients who had taken
intentional chloroquine overdoses, of whom 33 died (11%), and 16 healthy volunteers who took
620 mg base chloroquine single doses. Whole blood concentrations of 13.5 μmol/L (95% credible
interval 10.1-17.7) were associated with 1% mortality. Prolongation of ventricular depolarisation
is concentration-dependent with a QRS duration >150 msec independently highly predictive of
mortality. Pharmacokinetic modelling combined with these lethality data predicts that the
majority of chloroquine regimens trialled in COVID-19 should not cause serious cardiovascular
toxicity.

Introduction

Chloroquine and hydroxychloroquine are closely related 4-aminoquinoline drugs used for the treat-
ment of malaria, amoebiasis and rheumatological conditions (*World Health Organization, 2015*).
Until the late 1990s chloroquine was the drug of choice for the treatment of malaria. Hundreds
of tonnes corresponding to over 200 million doses were consumed annually. Since then its use
has declined because of widespread resistance in *Plasmodium falciparum*. Today there is greater
use of hydroxychloroquine in rheumatoid arthritis and discoid and systemic lupus erythematosus
(SLE). Chloroquine and hydroxychloroquine are both weak antivirals with a broad range of activi-
ties (including flaviviruses, retroviruses, and coronaviruses) (*Savarino et al., 2003*; *Liu et al., 2020*;
Wang et al., 2020; *Yao et al., 2020*; *Mégarbane and Scherrmann, 2020*). As of the 11th June 2020,
77 interventional clinical trials for evaluating these drugs in both the prevention and treatment of
COVID-19 were registered and recruiting participants on ClinicalTrials.gov. The relatively weak an-
tiviral activity against SARS-CoV2 in vero cell cultures has motivated trialling of higher loading and
maintenance doses than usually given in malaria or hepatic amoebiasis (*World Health Organiza-
tion, 2015*). This has caused concern over the potential for cardiovascular toxicity. Nevertheless,
despite the lack of any convincing evidence of clinical benefit, these drugs are now being used

extensively in COVID-19 prevention and treatment across the world. Sadly, patients who need hydroxychloroquine or chloroquine for the treatment of malaria and rheumatological conditions are often having difficulty obtaining them (*Straits Times, 2020*).

Borba et al. reported results from a randomised trial in Brazil of two dose regimens of chloroquine in COVID-19 treatment (*CloroCovid-19* study, ClinicalTrials.gov NCT04323527) (*Borba et al., 2020*). The trial was stopped early after recruiting only 81 patients because of cardiac toxicity and greater mortality in the higher dose group; two of 41 patients given the higher dose regimen developed ventricular tachycardia before death and 7 of 37 patients in this group developed electrocardiograph QTcF intervals over 500 msec compared with 4 of 36 in the lower dose group. The higher dose regimen, comprising 600 mg base chloroquine administered twice daily for ten days, is substantially higher than recommended in malaria or rheumatological conditions (*World Health Organization, 2015*) and represents the standard malaria loading dose repeated 19 times at 12 hour intervals.

Chloroquine is dangerous in overdose and has been used extensively for suicide. High concentrations of chloroquine cause hypotension, arrhythmias, coma, acute respiratory distress syndrome (ARDS), and fatal cardiac arrest (*Riou et al., 1988*; *Clemessy et al., 1995*, *1996*; *Mégarbane et al., 2010*). In Zimbabwe the mortality of chloroquine in overdose was approximately six times higher than for other drugs (*Ball et al., 2002*). In France in the early 1980s there was a suicide epidemic (*Riou et al., 1988*; *Clemessy et al., 1995*, *1996*; *Mégarbane et al., 2010*) following the publication of a book entitled *Suicide: mode d'emploi* (Suicide: a how-to guide) (*Guillon and Le Bonniec, 1982*). This unfortunate experience allowed characterisation of the factors associated with death from chloroquine overdose. Outcome in chloroquine self-poisoning depends on the dose ingested, the delay in reaching hospital and the quality of intensive care support. Using the blood concentration measurements taken from self-poisoning patients managed by experienced intensivists in the French National referral centre allowed development of a pharmacokinetic-pharmacodynamic model to estimate the relationship between chloroquine dosing and a fatal outcome. A pooled analysis using electrocardiograph QRS interval data from healthy volunteers (*Pukrittayakamee et al., 2014*) and from the French self-poisoning cohorts helped characterise the contribution of QRS prolongation to the recorded QT prolongation. These models were used to estimate the safety of the main treatment regimens currently used in COVID-19 clinical trials and to a standard malaria treatment regimen for comparison.

Results

Predicting mortality in self-poisoning from peak chloroquine concentrations

We pooled individual patient whole blood chloroquine + desethylchloroquine concentrations and outcomes from three large prospectively studied hospital self-poisoning cohorts (n=302, Figure 1, top panel) (*Riou et al., 1988*; *Clemessy et al., 1995*, *1996*; *Mégarbane et al., 2010*). All the patients included in this analysis were treated in the same hospital in Paris and all had whole blood concentrations measured on admission. The overall mortality was 11% (33 of 302). Of the patients with multiple concentration measurements ($n = 173$), 61 (35%) reached their peak whole blood chloroquine concentrations after admission. The distribution of differences on the log scale between admission concentrations and peak concentrations in patients who peaked after hospital admission was used to estimate a correction term for all other patients. Bayesian logistic regression was used to estimate the relationship between mortality and inferred whole blood peak chloroquine concentrations (Figure 1, bottom panel) specifically adjusted for the desethyl metabolite levels and for the non-observed peak concentrations in 241 (80%) of the patients. The model also adjusted for differences in treatment received between cohorts. The whole blood chloroquine concentration associated with 1% mortality was 13.5 μmol/L (95% C.I. 10.1 to 17.7). This is the lowest mortality for which a reliable estimate can be derived from these data. This threshold value was then used to evaluate the risk of fatal toxicity in chloroquine treatment regimens under evaluation in COVID-19.

Figure 1. Pharmacokinetic-pharmacodynamic model of chloroquine induced mortality. Top: pooled whole blood chloroquine + desethylchloroquine concentrations from admission samples in 302 prospectively studied self-poisoning patients (***Riou et al., 1988***; ***Clemessy et al., 1995***, ***1996***; ***Mégarbane et al., 2010***). The data are shown as overlapping histograms for survivors (yellow, $n = 269$) and fatal cases (red, $n = 33$). The overlapping areas are shown by the intermediate burgundy colour. Bottom: Bayesian posterior distribution over the concentration-response curve (mean and 95% credible interval) describing the relationship between inferred whole blood chloroquine peak concentrations (after adjustment for the deseythl metabolite) and death, with the chloroquine concentration shown on the $\log_{10}$ scale. The vertical lines show the upper 99 percentiles of the predicted C_{max} distribution in a 70 kg adult under the whole blood pharmacokinetic model for the six regimens considered (pink: 10 day regimen with maintenance dose of 600 mg; brown: 10 day regimen with maintenance dose of 310 mg; green: 7 day regimen with maintenance dose of 310 mg; grey: malaria regimen). The vertical light pink shaded area shows the posterior credible interval over the concentrations associated with 1% mortality. The equivalent output with the plasma pharmacokinetic model is shown in *Appendix 4*.

Predicting mortality from peak concentrations in COVID-19 treatment regimens

We used two pharmacokinetic models to predict peak chloroquine concentrations for six chloroquine regimens. Five of the simulated regimens are potential COVID treatment regimens, and one is the standard malaria treatment regimen. A very wide range of chloroquine and hydroxychloroquine regimens are currently in use for the treatment of COVID-19 (*Appendix 5*). The COVID-19 regimens we simulated correspond to the highest chloroquine treatment regimen (in terms of total dose) registered at ClinicalTrials.gov (*Borba et al., 2020*); the regimen given in the World Health Organisation SOLIDARITY trial (NCT04330690); a lower 7 day adaptation of the SOLIDARITY regimen; and weight-optimised equivalent regimens.

The pharmacokinetic model estimated from whole blood concentrations (*Höglund et al., 2016*) predicted a slightly wider range of values for maximum chloroquine concentrations (C_{max}) than the plasma based model (*Appendix 3* shows the predicted C_{max} distributions for both models in a 70 kg adult). Assuming a whole blood to plasma concentration ratio of 4, the whole blood based model and the plasma based model predicted approximately identical median C_{max} values. Thus, the whole blood pharmacokinetic model provides higher estimates for fatal toxicity because it predicts a larger variance for the C_{max} distribution and hence more extreme outliers. As a sensitivity analysis, the equivalent outputs for the plasma based model are shown in *Appendix 4*.

Based on the whole blood model, the median C_{max} following a chloroquine dose of 600 mg base equivalent given twice daily for ten days to a 70 kg adult is 10.7 μmol/L (Figure 2, panel A). This is more than 3 times higher than the median C_{max} for the chloroquine malaria treatment regimen at the same body weight. Approximately 60% of 70 kg adults continuing to receive the twice daily 600 mg dose enter the 'danger zone' defined as whole blood concentrations above 10 μmol/L. In comparison, only 2 in 1000 70 kg adults receiving the twice daily 310 mg maintenance dose (as given in the SOLIDARITY trial) for ten days would reach concentrations above 10 μmol/L. Taking into account the uncertainty around this threshold value, the model estimates that fewer than 1 per thousand receiving the twice daily 310 mg dose would have peak concentrations above the 1% mortality threshold (Figure 2, panel B). At most, 2 in a thousand 40 kg adults receiving the 3 day malaria treatment regimen (an unusually high mg/kg dose for malaria treatment) are predicted to reach peak concentrations above 10 μmol/L.

Coupling the pharmacokinetic model with the pharmacodynamic model, we estimated the expected weight-dependent fatality ratios for the five COVID-19 chloroquine treatment regimens, truncating the concentration-fatality curve at the 1% mortality threshold (only taking into account concentrations going above this threshold). Administering 600 mg base equivalent of chloroquine phosphate twice daily for ten days as in the *CloroCovid-19* trial is predicted to result in absolute mean fatality ratios ranging between 0.05% (90 kg, 95% credible interval (C.I.), 0 to 0.3%) and 3.5% (40 kg, 95% C.I. 1.0 to 8.0%), Figure 2, panel C. In comparison, only the flat dosing regimens are predicted to result in fatality ratios greater than 1 per thousand and then only for weights less than 55 kg: for a 40 kg adult the 10 day SOLIDARITY regimen could result in 0.2 per thousand mortality (95% CI, 0 to 0.8). The 10 day flat regimen (without a loading dose) was recommended by the Health Commission of Guangdong Province for adults weighing more than 50 kg (*Multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia., 2020*). The model predictions suggest that reduced doses should be given at the lower end of the adult weight spectrum.

Concentration-dependent electrocardiograph QRS prolongation

We pooled individual electrocardiograph QRS intervals and chloroquine concentration data from 16 healthy volunteers (*Pukrittayakamee et al., 2014*, for each individual, the QRS interval was measured twice at rest and 12 times in presence of detectable plasma chloroquine concentrations after a single 620 mg base oral dose of chloroquine) and 290 self-poisoning patients (no QRS data from *Riou et al.*, and one missing QRS measurement from the Clemessy cohort), Figure 3. We fitted a

Figure 2. The predicted risk of fatal toxicity across the six regimens simulated under the whole blood pharmacokinetic model. Panel A shows the simulated distribution of C_{max} values in a 70 kg adult for the five COVID-19 treatment regimens under evaluation and the standard malaria treatment regimen. The vertical light pink shaded area shows the 95% credible interval for the 1% mortality threshold concentration. Panel B shows the probability that an individual will cross the 1% mortality threshold value as a function of body weight for the different regimens ($\log_{10}$ scale on the y-axis). Panel C shows the predicted mortality per thousand for the six regimens as a function of body weight. The equivalent output using the plasma pharmacokinetic model is given in *Appendix 4*.

hierarchical Bayesian Emax sigmoid regression model to the paired concentration-QRS data and
the steady state QRS data (healthy volunteers only), a total of $n = 514$ datapoints. A whole blood
chloroquine concentration of 3 μmol/L (usually observed in malaria treatment) is associated with
a slight QRS prolongation of 6.7 msec (95% credible interval, 5.5 - 7.8). Clinically significant intra-
ventricular conduction delay (QRS prolongation), resulting in durations greater than 150 msec, was
strongly associated with observed chloroquine concentrations above 10 μmol/L. In self-poisoning,
1 out of 108 patients with admission whole blood concentrations less than 10 μmol/L had a QRS
interval longer than 150 msec (this accounts for the bias term estimated in the Clemessy cohort).
In comparison, QRS durations longer than 150 msec were recorded in 36 out of 182 (20%) of the
patients with whole blood concentrations greater than 10 μmol/L. In self-poisoning patients, QRS
duration was an independent predictor of death (adjusted odds ratio for death of 1.3 for each 10
msec increase in QRS, $p < 10^{-5}$).

Discussion

Chloroquine is dangerous in overdose. The risk of death is proportional to drug exposure. Mor-
tality rises steeply at whole blood chloroquine concentrations above 10 μmol/L. This corresponds
very approximately to a plasma concentration of 3 μmol/L, and a combined chloroquine and de-
sethylchloroquine concentration (as in a spectrophotometric assay) of 14 μmol/L. Importantly the
electrocardiograph is a valuable indicator of toxicity as potentially lethal levels are associated with
significant QRS complex widening. A QRS duration of less than 100 msec makes lethal toxicity very
unlikely. When using high-dose treatments weight adjusted dosing is important to avoid toxicity.

Implications for COVID treatment regimens

Chloroquine and hydroxychloroquine are already being used extensively, and often in high doses,
to prevent and treat COVID-19 despite the current lack of convincing evidence of benefit. Use of
these drugs has become extremely politicised. The first large randomised trial in the treatment of
hospitalised patients has just reported (RECOVERY, NCT04381936: press release only at the time of
writing, results are not yet peer reviewed). The prevention trials will take longer to report. Confu-
sion over the risks associated with chloroquine and hydroxychloroquine has been compounded by
a recent high profile claim of increased mortality and high rates of ventricular arrhythmia in a very
large observational data set that was almost certainly fabricated (and the paper subsequently re-
tracted), and by misunderstanding of their clinical pharmacology. Chloroquine and hydroxychloro-
quine have unusual pharmacokinetic properties with enormous total apparent volumes of distribu-
tion (V_d) (chloroquine > hydroxychloroquine) and very slow elimination (terminal half-lives exceed
one month). Thus, distribution processes, rather than elimination, govern the blood concentration
profiles in the first days following the start of treatment. Large single doses (as in self-poisoning) are
very dangerous because they result in high blood concentrations as the drugs distribute out from a
central "compartment" that is hundreds of times smaller than the total apparent V_d (compartmen-
tal modelling of chloroquine pharmacokinetics provides only an approximation of the distribution
processes). These high concentrations can cause potentially lethal cardiovascular and nervous
system toxicity. Chloroquine affects cardiac muscle depolarisation, repolarisation and contractility
and also causes vasodilatation. There is concentration dependent electrocardiograph QRS widen-
ing and JT prolongation (*Clemessy et al., 1995*, *1996*) which both contribute to QT prolongation.
Death usually results from refractory hypotension or ventricular fibrillation. Self-poisoning with
chloroquine has provided an unfortunate opportunity to correlate drug exposure with the risk of
iatrogenic death.

As chloroquine has weak antiviral activity, if there is benefit in COVID-19 infections, it is likely
to require high drug exposures. At the beginning of the COVID-19 pandemic a large number of in-
vestigators started studies of chloroquine and hydroxychloroquine. The toxicity thresholds were
not well defined and a range of dose regimens were evaluated, some of which have been very
high (Appendix, Figure 5). The high dose chloroquine regimen evaluated by *Borba et al.* which did

Figure 3. Electrocardiograph QRS interval duration as a function of whole blood chloroquine concentrations. The data shown in the scatter plot are from 16 healthy volunteers who took a single 620 mg base oral dose (green circles, 192 paired concentration-QRS data-points, plasma concentrations were multiplied by 4) and 290 chloroquine self-poisoning patients (red and blue, hospital admission concentrations). Random normal jitter (standard deviation of 1 msec) was added to the Clemessy cohort self-poisoning QRS values for improved visualisation. Survivors are shown as circles and fatal cases as triangles. The self-poisoning QRS values from the Clemessy series (*Clemessy et al., 1995*, *1996*) were manually read and are adjusted for a bias term (see Methods, non-adjusted data are shown in *Appendix 6*). The grey line (grey area) shows the estimated median QRS duration (range) in the 16 healthy volunteers in absence of measurable drug. The thick black line shows the mean posterior Emax sigmoid regression model, fitted to the pooled data. The dashed green and blue lines show the posterior predictive distribution under the error distributions for the healthy volunteers and Megarbane self-poisoning cohort (smaller measurement error than in the Clemessy cohort), respectively (see Methods for the full specification of the model). Note that the Emax regression model does not account for concentration-dependent heteroskedasticity but only inter-individual variation for healthy volunteers and inter-study variation (differences in measurement).

encounter cardiac toxicity referenced the recommendations by the Health Commission of Guang-
dong Province, but there may have been confusion between salt and base weights (*Multicenter
collaboration group of Department of Science and Technology of Guangdong Province and Health
Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneu-
monia., 2020*). The Chinese authorities recommended 500 mg *salt* twice daily (two tablets of 250
mg, comprising 155 mg base each) whereas the Brazil study (*Borba et al., 2020*) gave doses in
base equivalent (which were consequently much higher) . Importantly the patients in the Brazil-
ian study also received azithromycin (which also prolongs the QT interval, and this may well have
contributed to ventricular arrhythmias *Saleh et al., 2020*; *Lane et al., 2020*). Nevertheless this phar-
macometric analysis of the self-poisoning cohorts provides an evidence-based toxicity threshold
and it does suggest that a continued regimen of 600mg twice daily can be directly lethal. Lower
dose regimens such as those evaluated in the large RECOVERY and SOLIDARITY trials, and the orig-
inal Guangdong study, are predicted to be safe. Doses of chloroquine alone, resulting in peak
concentrations greater than 10 μmol/L are associated with more than 1% risk of fatal toxicity.

Limitations

There are several limitations to this study. It is a retrospective individual patient data analysis.
In the suicide attempts, other drugs or alcohol were often taken as well, although none with the
acute lethal toxicity of chloroquine. Patients were managed by experienced intensivists on inten-
sive care units where there was close clinical and laboratory monitoring. Mortality might be higher
in less well supported settings, or in overloaded hospitals in high-income settings. The age range
in self-poisoning is also younger than in the majority of more seriously ill COVID-19 patients. The
spectrophotometric assay method does not separate chloroquine from its desethylated metabo-
lite, and is relatively insensitive. Desethychloroquine has generally similar biological properties,
and the assay performs well at the high concentrations of relevance to this study. We corrected
for the presence of the metabolite under the Bayesian model, but this correction increases uncer-
tainty around the threshold concentration associated with 1% mortality. The predictions of abso-
lute mortality under the regimens simulated in this work are sensitive to the parameterization of
the pharmacokinetic model. C_{max} is not observed directly but is an output model-based quantity
estimated from data. There are no large population pharmacokinetic studies to verify the precision
of the C_{max} predictions, especially for the critical upper tails of the distribution.

The pharmacokinetic-pharmacodynamic model developed here was based on the largest prospec-
tive series of chloroquine self-poisonings studied in a single referral centre. However, it was not
possible to apply a standard pharmacokinetic model to the observed data in order to estimate the
individual C_{max} values. Mainly because of vomiting, admission blood concentrations only weakly
correlate with the self-administered chloroquine doses (*Clemessy et al., 1995*). Our model was
based on a majority of admission whole blood concentrations. The data from patients whose peak
drug concentrations occurred after hospital admission were used to approximate the difference
between unobserved peak concentrations and admission concentrations in the remaining patients.
Overall, the admission concentrations were estimated to be approximately 5% lower on average
than the peak concentrations. This corresponds to prior expectations: the mean interval to hos-
pitalisation for this large self-poisoning cohort was 4.5 hours compared with an average time to
peak concentration after oral administration of 3 hours (range 1-6 hours) (*Pukrittayakamee et al.,
2014*). The outcome of chloroquine poisoning depends on the quality of intensive care support.
Over the period of this retrospective review, in addition to the experience gained in this one re-
ferral centre, there were significant improvements in intensive care which would have improved
the prognosis for a given drug exposure. Sustaining the cardiorespiratory system mechanically
with extracorporeal membrane oxygenation (*Mégarbane et al., 2007*) while toxic concentrations
decline as the drug distributes may have made a significant contribution to improved survival.

Our analysis does not make specific predictions for the toxicity of hydroxychloroquine regimens
currently in use for the treatment of COVID-19. The majority of clinical trials are evaluating hydrox-

ychloroquine, not chloroquine, as it is considered to be slightly safer and is more widely available
in the countries where most trials are being conducted. Although hydroxychloroquine has a wider
therapeutic margin in experimental animals (*McChesney, 1983*), it has generally similar pharma-
cokinetic properties and, although there are limited data, the pharmacodynamic properties are
also generally similar to chloroquine. The clinical features of hydroxychloroquine and chloroquine
in overdose are also similar. But unlike chloroquine, there are no large cohorts of hydroxychloro-
quine self-poisoning on which to define toxicity thresholds. Thus, given available toxicity data, it
is very unlikely that equivalent hydroxychloroquine concentrations to chloroquine are more dan-
gerous, but rather that the safety margins are wider. Our systematic review of regimens currently
being used for the treatment of COVID identifies one trial currently recruiting patients (PATCH,
NCT04329923) which is administering very high doses of hydroxychloroquine (*Appendix 5*). This
dose of 1200mg/day (930 mg base/day) for 14 days would be predicted to have a significant risk of
incurring dangerous toxicity were hydroxychloroquine and chloroquine to have molar equivalent
toxicities. However the majority of regimens currently being tested for COVID-19 treatment are
predicted to be safe.

Electrocardiograph QT concerns limit COVID-19 studies

Concerns over QT prolongation dominate the reasons for not endorsing or not participating in
COVID 19 trials with chloroquine or hydroxychloroquine. Many recent articles on COVID-19 ther-
apeutics caution against the risks of iatrogenic "torsade de pointes" (TdP) with these drugs (*Pa-*
stick et al., 2020; *Monzani et al., 2020*; *Chary et al., 2020*; *Guzik et al., 2020*; *Guastalegname and*
Vallone, 2020; *van den Broek et al., 2020*; *Jeevaratnam, 2020*; *Sapp et al., 2020*). Both drugs do
cause significant QT prolongation and, whilst they block several different cation channels affect-
ing myocardial depolarization (resulting in QRS prolongation) and repolarization (resulting in JT
prolongation), the multichannel block is considered unbalanced, and both drugs are regarded as
"torsadagenic" (*Vicente et al., 2018*). Many of the recent reports rediscovering this well known
effect omit description of the contribution of QRS widening to QT prolongation (and thereby over-
estimate JT prolongation). Approximately 350 tonnes of hydroxychloroquine are manufactured
each year, almost all of which is used for rheumatological conditions, so millions are receiving long
term regimens. Many of these have systemic lupus erythematosus which is commonly associated
with myocarditis, QT prolongation, and a high prevalence of arrhythmias (*Gawałko et al., 2020*;
Bourré-Tessier et al., 2015). Reviews and authoritative websites all state that hydroxychloroquine
causes TdP. Yet despite this enormous use in a systematic review of the literature we can find only
a single reported case of TdP outside of COVID-19 treatment. This was in a 67 year old Taiwanese
female with systemic lupus erythematosus, cirrhosis and a previous myocardial infarct who was
receiving hydroxychloroquine (*Chen et al., 2006*). The patient survived. The WHO pharmacovigi-
lance database (VigiBase) contains reports of 83 episodes of ventricular tachycardia associated with
hydroxychloroquine over a 52 year period of which 7 were fatal (this does not distinguish acute tox-
icity from the well described chronic toxic cardiomyopathy associated with use over many years).
Overall, in systemic lupus erythematosus, patients receiving chloroquine have fewer arrhythmias
than those on other medicines (*Alkmim Teixeira et al., 2014*; *Wozniacka et al., 2006*). In a very
large retrospective observational study of 956,374 patients with rheumatoid arthritis starting hy-
droxychloroquine, there were significantly less arrhythmias in the first month of treatment with hy-
droxychloroquine compared to patients (N=310,350) started on sulphasalazine (*Lane et al., 2020*).
This reflects the under-recognised anti-arrhythmic effects of these drugs (*Harris et al., 1988*). In
COVID-19 treatment there have been two reports so far of TdP. An 84 year old Israeli woman with
metastatic breast cancer who was taking bisoprolol, letrozole and memantine and received chloro-
quine treatment (*Szekely et al., 2020*), and a 68-year-old American male given hydroxychloroquine
and azithromycin (*Chorin et al., 2020*). Neither of these episodes were fatal. In Europe and the
USA, where chloroquine and hydroxychloroquine are allowed for compassionate use, there have
been more than 250,000 deaths from COVID-19. The apparently low rates of reported ventricular

arrhythmia are surprising given that evidence of myocarditis in lethal COVID-19 is common (**Kang et al., 2020**; **Long et al., 2020**). Except in deliberate self-poisoning TdP has not been reported with chloroquine either, despite billions of malaria treatments and extensive use in rheumatological conditions and hepatic amoebiasis for over 70 years. Thus it appears that the individual risk over the short term with currently used doses is very low. Subjects with pre-existing long QT intervals, electrolyte imbalance, concomitant QT prolonging medications (notably azithromycin in COVID-19) and structural heart disease are likely to be at greater individual risk. The very low risks of drug induced arrhythmia over the short term should be distinguished from long term cumulative cardiotoxicity. The main cardiac concerns with long term usage of chloroquine and hydroxychloro-quine are conduction defects and cardiomyopathy (**Tönnesmann et al., 2013**).

In summary, despite causing significant QT prolongation, there is no evidence that the risks of TdP and sudden death with chloroquine and hydroxychloroquine at currently recommended doses over the short term are increased above those of the background population. Restricting the evaluation of these drugs in COVID-19 for this specific concern therefore seems unwarranted. In assessing the potential toxicity of these drugs QRS widening correlates with severity.

Risk-benefit assessment in the treatment of COVID-19

COVID-19 ranges from very mild illness to severe disease necessitating intensive care. Case fatality ratios are highly age dependent (**Wu et al., 2020**). The potential toxicity of a treatment regimen has to be balanced against the severity of illness. If chloroquine is to benefit patients with COVID-19 it is likely to require high exposures. Understanding the concentration-dependent toxicity of chloroquine is essential in assessing the risk-benefit trade-off in COVID-19 clinical trials. This is evidence based whereas the presumption of risk from lethal TdP derived from the measurement of electrocardiograph QT prolongation (which dominates the current literature) is not. From a clinical perspective there are several practical implications of these observations in self-poisoning. If high doses of chloroquine or hydroxychloroquine are being given to hospitalised patients and blood concentrations cannot be measured rapidly (which is the usual situation) then electrocardio-graphic monitoring is informative. QRS interval widening can be used as an indicator of toxicity. If the QRS interval is less than 100 msec then serious cardiovascular toxicity is very unlikely. JT interval prolongation is expected, but it is often harder to assess (as the end of T wave definition is often unclear). Hypokalaemia is an important manifestation of chloroquine poisoning and a con-tributor to tachyarrhythmias (**Clemessy et al., 1995**). With high dose regimens plasma potassium concentrations should be maintained over 4.0 mmol/L and plasma magnesium concentrations over 0.8 mmol/L. Overall treatment regimens for hospitalised COVID-19 patients which result in whole blood chloroquine concentrations below 10 μmol/L for more than 95% of patients have an acceptable safety margin.

Methods and Materials

Patient data

The largest prospectively studied cohorts of self-poisoning with chloroquine have all been assem-bled by the national clinical toxicology unit in Paris, France (Réanimation Médicale et Toxicologique, Hôpital Lariboisière). The clinical and laboratory characteristics of these cohorts have been pub-lished in detail previously (**Riou et al., 1988**; **Clemessy et al., 1995**, **1996**; **Mégarbane et al., 2010**). The extensive experience gathered in this clinical toxicology unit established the standard of care for chloroquine poisoning, including mechanical ventilation, appropriate sedation and optimum use of inotropes and vasopressors. Pre-hospital care was provided by emergency physicians in mobile intensive care units. These units could perform 12-lead electrocardiograms as well as ad-vanced life support. Whole blood chloroquine concentrations were measured on admission and at varying times subsequently. The whole blood chloroquine concentrations following self-poisoning were determined using ultraviolet spectrophotometry at a wavelength of 343 nm. This analytical

method does not differentiate between chloroquine and the biologically active desethyl metabolite.

Original drug concentration measurements, electrocardiograph QRS durations and outcome data were available for all prospectively studied patients from 1987 to 1994 (*Clemessy et al., 1995, 1996*) and a later cohort studied from 2003 to 2007 (*Mégarbane et al., 2010*). Patients were included in the prospective studies if there was a history of attempted suicide and chloroquine was present in the admission whole blood sample. For all patients studied prospectively between February 1987 and January 1992 ($n = 167$ *Clemessy et al., 1996*) multiple whole blood chloroquine measurements were taken during the first 48 hours of hospital stay. The number and timing of samples varied between cases. Original data were not available for *Riou et al.* (*1988*) so concentrations and outcomes were extracted from graphs in the publication (Figure 3 in *Riou et al., 1988*). Whole blood chloroquine concentrations and outcome could be determined approximately for all 102 patients. Data were extracted using the web version of WebPlotDigitizer (https://automeris.io/WebPlotDigitizer/).

Electrocardiograph QRS durations were manually read for all patients in *Clemessy et al.* (*1995*, 1996). Automated and manual readings were used for patients in *Mégarbane et al.* (*2010*). We did not have reliable QT interval measurements for the chloroquine self-poisoning patients. It is often impossible to determine accurately the end of the T wave in the presence of the extremely high chloroquine concentrations observed in self-poisoning (in the 10-100 μmol/L range). Several case reports of massive chloroquine overdose show illustrative electrocardiograms in which the QT interval is difficult or impossible to measure accurately, e.g. *Gunja et al.* (*2009*); *de Olano et al.* (*2019*). An ECG typical of chloroquine self-poisoning, with substantial QRS widening and moderate JT prolongation, is shown in *Appendix 7*.

To characterise the relationship between chloroquine concentrations and QRS prolongation, we used plasma chloroquine concentration measurements (from solid phase extraction and high performance liquid chromatography with UV detection) and electrocardiograph QRS interval measurements from 16 healthy volunteers who took single 620 mg dose of chloroquine base orally (*Pukrittayakamee et al., 2014*, we note that in the original publication it states that this was a 600mg single dose, but this is a typographic error). The healthy volunteer QRS data consisted of 32 measurements in the absence of drug (two separate occasions for each volunteer) and 192 (12 per volunteer) paired chloroquine concentration-QRS measurements.

Literature review

We conducted a literature review of all published case reports and hospital cohorts on chloroquine poisoning. We extracted data from 12 case reports (13 patients) in which whole blood or plasma chloroquine concentrations were reported. We analysed only case reports in which blood or plasma concentrations were obtained ante-mortem as the post mortem redistribution of chloroquine from tissues to the blood is unknown. However, the data from the case reports exhibited significant bias towards patients with high concentrations who survived (i.e. unusual cases) so these were excluded from the final model. To review reports of Torsade de Pointes associated with chloroquine or hydroxychloroquine PubMed and EmBase were searched using the terms 'HYDROXYCHLOROQUINE' or 'CHLOROQUINE' AND either 'TORSADE', 'ARRHYTHMIA', 'SUDDEN DEATH' or 'CARDIAC ARREST'.

We searched ClinicalTrials.gov on the 11th of June 2020 (https://clinicaltrials.gov/ct2/home) for clinical trials using hydroxychloroquine and chloroquine for the treatment of COVID-19 (search terms: condition=COVID; other terms=hospital; intervention=hydroxychloroquine OR Chloroquine; status=recruiting). This gave 77 results. After filtering out prevention studies, we could determine the total dose in base equivalent for 55 treatment studies (these are presented in a supplementary file).

Pharmacokinetic modelling

Chloroquine has complex pharmacokinetic properties characterised by an enormous volume of distribution and a terminal elimination half-life of over a month. Whole blood (the currently preferred matrix) concentrations are significantly higher than plasma concentrations because of binding to red blood cells, leukocytes and platelets. Two models were used for simulation in NONMEM (v.7.4.3, Icon Development Solution, Ellicott City, MD; the NONMEM simulation code is available online; see github repository link below). The first was a published two-compartment disposition model with a transit compartment absorption model using whole blood measurements from adult vivax malaria patients treated with a standard 25 mg base/kg regimen over three days (*Höglund et al., 2016*) ($n = 75$, with over 1000 concentrations measurements). Allometric scaling of body weight, with the exponent fixed to 0.75 for clearance parameters and 1 for volume parameters, was added to the published model to predict concentrations at different body weights. The second was a three-compartment model with the absorption described by a transit compartment model fitted to plasma chloroquine concentrations from healthy adult volunteers who took oral single 600 mg base equivalent doses of chloroquine on two separate occasions with or without primaquine (*Pukrittayakamee et al., 2014*, $n = 16$, a total of 640 concentration measurements: each volunteer was sampled 20 times at two separate dosing occasions; the model is not yet published). This model included allometric scaling as described above. Published estimates for the plasma to blood ratio vary considerably (reviewed in *Mégarbane et al., 2010*). We choose a scaling ratio of 4 as this resulted in equal median concentrations for both pharmacokinetic models and is approximately the median value from the review in *Mégarbane et al.* (*2010*).

Five potential chloroquine COVID-19 adult treatment regimens, and one malaria treatment regimen were simulated:

1. 600 mg base, twice daily for 10 days, as trialled in Brazil, no loading dose was given (*Borba et al., 2020*).
2. 620 mg base loading dose at 0 and 6 hours, followed by 310 mg base twice daily (starting at 12 hours) for nine days. Except for the loading dose, this is equivalent to the regimen recommended by the Health Commission of Guangdong Province (*Multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia., 2020*). This is the regimen given in the World Health Organisation SOLIDARITY trial.
3. 620 mg base loading dose on day 1 at 0 and 6 hours, followed by 310 mg base twice daily (starting at 12 hours) for six days.
4. Weight-adjusted dosing regimen targeting loading doses at 0 and 6 hours of 10 mg base/kg, followed by maintenance doses of 5 mg/kg for 9 days (starting at 12 hours), approximated to the nearest 155 mg base whole tablets.
5. Weight-adjusted dosing regimen targeting loading doses at 0 and 6 hours of 10 mg base/kg, followed by maintenance doses of 5 mg/kg for 6 days (starting at 12 hours), approximated to the nearest 155 mg base whole tablets.
6. A "flat" standard malaria dosing regimen of 620 mg base on days 1 & 2, followed by 310 mg base on day 3, for the same range of weights.

Regimens 1-3 & 6 are "flat" dosing regimens (i.e. not weight-based). All regimens were simulated for weights ranging from 40 to 90 kg at intervals of 5 kg.

Concentration-dependent model of death in chloroquine self-poisoning

We compared the relationship between admission whole blood chloroquine + desethyl metabolite concentration and death using logistic regression (maximum likelihood fit) for data gathered retrospectively ($n = 91$ *Riou et al., 1988*) and data collected prospectively ($n = 302$ *Riou et al., 1988*; *Clemessy et al., 1995*, *1996*; *Mégarbane et al., 2010*). The retrospective data gave substantially different results with much higher probabilities of death (approximately 60% versus 5% at $20\,\mu$mol/L,

435 see *Appendix 1*). We therefore excluded the 91 retrospectively studied patients reported in *Riou*
436 *et al.* but retained the 11 prospectively studied patients from that publication. This gave a total of
437 302 unique patient observations.

438 We modelled the probability of death as a function of the log whole blood peak chloroquine
439 concentration (μmol/L) using Bayesian logistic regression. The peak concentration is considered
440 a latent variable (unobserved) for patients whose blood concentrations peaked before hospital
441 admission or for patients who only had their whole blood concentration measured on admission
442 ($n = 241$). The peak concentration is considered observed for those who had multiple concentra-
443 tion measurements and for whom the peak occurred after hospital admission ($n = 61$). The model
444 does not attempt to estimate individual peak concentrations for the patients whose peak concen-
445 trations were unobserved, but rather an average difference δ, on the log scale, between peak and
446 admission concentrations (this can be considered as a bias correction term). This assumes that the
447 probability of death, conditional on the peak drug concentration, was the same for those whose
448 blood concentrations peaked before and after hospital admission. This assumption is likely to be
449 incorrect. Patients whose levels peaked after hospital admission would have received supportive
450 hospital care more rapidly (relative to time of peak concentration) than those who peaked before
451 admission. However, the extent of this bias is unmeasurable.

452 In addition, the model adjusted for differences in hospital treatment received between the
453 three cohorts: cohort 1 was the 11 prospectively studied patients in *Riou et al.* (*1988*); cohort 2
454 was the 247 studied in *Clemessy et al.* (*1995*, 1996) (named herein 'the Clemessy cohort'); cohort 3
455 was the 44 patients studied in *Mégarbane et al.* (*2010*). Substantial differences in standard of care
456 occurred between these three cohorts. For example, the use of emergency extracorporeal life sup-
457 port started in the early 2000s and is thought to considerably reduced mortality *Mégarbane et al.*
458 (*2007*). The prior over the study specific intercept terms was a normal distribution with mean 0 and
459 standard deviation 0.5.

460 To model the relationship between whole blood chloroquine concentrations and a fatal out-
461 come we use a correction factor γ to account for the desethyl metabolite included in the assay
462 measurement. Between 1 and 6 hours post ingestion, the desethyl metabolite will account for ap-
463 proximately 30% of the total concentration measured (*Pukrittayakamee et al., 2014*). The values
464 of γ and δ are not directly identifiable from the data, but there are good *a priori* estimates for δ
465 (*Pukrittayakamee et al., 2014*). The data from the individuals whose levels peaked after hospital
466 admission were used to construct an informative prior distribution for γ.

467 The Bayesian posterior distribution over the model parameters used informative prior distribu-
468 tions for all four parameters. For the intercept term α, this was a normal distribution with mean
469 -15 (e.g. 1 in 10^7 chance of dying at a whole blood concentration of 1μmol/L), and standard devia-
470 tion 1; for the β coefficient on the $\log$ concentration, it was a normal distribution with mean 4 and
471 standard deviation 1. The bias term δ was given an exponential prior with rate 8 (estimated from
472 the 57 individuals whose levels peaked after hospital admission). The metabolite correction factor
473 γ was given a normal prior with mean 0.7 and standard deviation 0.065 (the standard deviation
474 was estimated from chloroquine and metabolite measurements in 107 malaria patients from *Chu*
475 *et al.* (*2018*)).

Coupled pharmacokinetic model and concentration-fatality model

477 For each chloroquine regimen and each weight category considered, we simulated 1,000 pharma-
478 cokinetic profiles. The simulation was run from the time of the first dose until 7 hours after the
479 last dose (7 hours will adequately capture the C_{max} value). Each simulated pharmacokinetic profile
480 was summarised by the peak concentration denoted C_{max}. The set of C_{max} values were then used
481 to predict mean fatality ratios using the concentration-fatality model estimated from the chloro-
482 quine self-poisoning data (herein referred to as the pharmacodynamic model). We propagated
483 uncertainty from the pharmacodynamic model by estimating desired quantities using 4000 ran-
484 dom draws from the posterior distribution. For the estimation of mortality under the different reg-

imens, we truncated the concentration-dependent mortality prediction at 1% (the concentration
at which this truncation occurs will vary depending on the draw from the posterior distribution).
This is because estimating mortality ratios below 1% is unreliable given a sample size of a few hun-
dred and will be highly dependent on the prior distribution chosen and the parametric form of the
concentration-fatality curve. For example, the posterior predictive model estimates a mortality of
the order of 1 per 100,000 at 2μmol/L. This is approximately the background rate of sudden unex-
plained death in a young adult population (***Chan et al., 2018***), therefore rendering the prediction
essentially unverifiable (non-scientific).

Concentration-dependent model of QRS widening

494 We estimated the relationship between chloroquine concentrations and QRS interval duration by
495 fitting a Bayesian sigmoid Emax model. The likelihood function of the regression model was spec-
496 ified as:

$$QRS_i \sim \text{Normal}\left(E_{\max} - \frac{E_{\max} - E_{\min}}{1 + e^{k(\log_{10} x_i - E_{50})}}, \epsilon_i^{(j)}\right), \quad j = \{1, 2, 3\} \tag{1}$$

where QRS_i is the observed QRS duration and x_i is the chloroquine concentration for individ-
ual i. This concentration is simultaneously measured (plasma converted to whole blood) for the
healthy volunteers, and is the admission chloroquine concentration (70% of measured whole blood
concentration to remove the metabolite contribution) for the self-poisoning patients. The standard
error ϵ is modelled separately for the self-poisoning patients and the healthy volunteers. This helps
to partially adjust for the concentration-dependent heteroskedasticity in QRS values and the differ-
ences in measurement error between pooled datasets (manually read ECGs in the Clemessy cohort
and much harder to correctly read at the high concentrations seen in self-poisoning (cohorts & 3)
versus automated reading in the healthy volunteer data).

The data from the self-poisoning patients are considered independent and identically distributed
conditional on the sigmoid regression model and the study cohort. The prior for the error term
$\epsilon_i^{(1)}$ for the Clemessy cohort was a normal distribution with mean 25 and standard deviation 5. The
prior for the error term $\epsilon_i^{(2)}$ for cohort 3 was a normal distribution with mean 20 and standard
deviation 5.

The data from the healthy volunteers are analysed with a hierarchical error model (also known
as a mixture model). We estimate an individual intercept term for each volunteer (the prior distri-
bution over intercept terms was a normal with mean 0 and standard deviation σ_{HV}; the prior over
σ_{HV} was an exponential distribution with rate parameter 0.2 corresponding to a standard devia-
tion of 5 msec in normal QRS values between individuals). The measurement error model, $\epsilon_i^{(3)}$, was
then given a normal prior with mean 5 and standard deviation 3). The QRS interval data from the
healthy volunteers taken in absence of drug were used to estimate the mean increase in QRS at
detectable drug levels (the difference between $E_{\min}$ and the mean QRS when no drug is detectable).

From a visual check of the raw QRS data (***Appendix 6***), the QRS values from the Clemessy series
appear to slightly biased downwards, and so we model this with an additional bias term (prior is a
normal distribution with mean -20 and standard deviation 5). $E_{\max}$ is the maximum mean QRS dura-
tion (prior is a normal distribution with mean 180 and standard deviation 10); $E_{\min}$ is the minimum
mean QRS duration (prior is a normal distribution with mean 90 and standard deviation 4); E_{50} is
$\log_{10}$ chloroquine concentration that results in a mean QRS duration of half the maximal increase
(prior is a normal distribution with mean 1.3 and standard deviation 1); the slope parameter k is
modelled on the log scale (prior is a normal distribution with mean 1 and standard deviation 1).
The prior distribution over the hierarchical intercept terms for the healthy volunteers was a nor-
mal distribution with mean 0 and standard deviation σ_i which was given an exponential prior with
rate 0.2.

Statistical analysis

Both Bayesian regression models were fitted to data using *stan* (*Carpenter et al., 2017*), implemented in *R*. Uncertainty around each fit was reported as centred 95% credible intervals. For each model 10^5 posterior samples were drawn from 8 independent chains, the first half were discarded for burn-in and second half thinned every 100 samples. This resulted in 4000 posterior samples used to characterise the posterior distributions. Mixing was assessed by agreement between chains and traceplots. Comparison of prior and posterior distributions are given in *Appendix 2*.

Code and data availability

All code (including the NONMEM simulation scripts) and data can be found on github at:

https://github.com/jwatowatson/Chloroquine-concentration-fatality.

References

Alkmim Teixeira R, Borba EF, Pedrosa A, Nishioka S, Viana VS, Ramires JA, Kalil-Filho R, Bonfá E, Martinelli Filho M. Evidence for cardiac safety and antiarrhythmic potential of chloroquine in systemic lupus erythematosus. Europace. 2014; 16(6):887–892.

Ball D, Tagwireyi D, Nhachi C. Chloroquine poisoning in Zimbabwe: a toxicoepidemiological study. Journal of Applied Toxicology: An International Journal. 2002; 22(5):311–315.

Borba MGS, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Brito M, Mourão MPG, Brito-Sousa JD, Baía-da Silva D, Guerra MVF, Hajjar LA, Pinto RC, Balieiro AAS, Pacheco AGF, Santos J James Dean Oliveira, Naveca FG, Xavier MS, Siqueira AM, Schwarzbold A, Croda J, et al. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. JAMA Network Open. 2020 04; 3(4.23):e208857–e208857. https://doi.org/10.1001/jamanetworkopen.2020.8857, doi: 10.1001/jamanetworkopen.2020.8857.

Bourré-Tessier J, Urowitz MB, Clarke AE, Bernatsky S, Krantz MJ, Huynh T, Joseph L, Belisle P, Bae SC, Hanly JG, et al. Electrocardiographic findings in systemic lupus erythematosus: data from an international inception cohort. Arthritis care & research. 2015; 67(1):128–135.

van den Broek M, Möhlmann J, Abeln B, Liebregts M, van Dijk V, van de Garde E. Chloroquine-induced QTc prolongation in COVID-19 patients. Netherlands Heart Journal. 2020; p. 1.

Carpenter B, Gelman A, Hoffman MD, Lee D, Goodrich B, Betancourt M, Brubaker M, Guo J, Li P, Riddell A. Stan: A probabilistic programming language. Journal of Statistical Software. 2017; 76(1).

Chan XHS, Win YN, Mawer LJ, Tan JY, Brugada J, White NJ. Risk of sudden unexplained death after use of dihydroartemisinin–piperaquine for malaria: a systematic review and Bayesian meta-analysis. The Lancet Infectious Diseases. 2018; 18(8):913–923.

Chary MA, Barbuto AF, Izadmehr S, Hayes BD, Burns MM. COVID-19: therapeutics and their toxicities. J Med Toxicol. 2020; 16(3):10–1007.

Chen CY, Wang FL, Lin CC. Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia. Clinical Toxicology. 2006; 44(2):173–175.

Chorin E, Wadhwani L, Magnani S, Dai M, Shulman E, Nadeau-Routhier C, Knotts R, Bar-Cohen R, Kogan E, Barbhaiya C, Aizer A, Holmes D, Bernstein S, Spinelli M, Park DS, Stefano C, Chinitz LA, Jankelson L. QT Interval Prolongation and Torsade De Pointes in Patients with COVID-19 treated with Hydroxychloroquine/Azithromycin. Heart Rhythm. 2020 05; https://doi.org/10.1016/j.hrthm.2020.05.014, doi: 10.1016/j.hrthm.2020.05.014.

Chu CS, Phyo AP, Lwin KM, Win HH, San T, Aung AA, Raksapraidee R, Carrara VI, Bancone G, Watson J, et al. Comparison of the cumulative efficacy and safety of chloroquine, artesunate, and chloroquine-primaquine in Plasmodium vivax malaria. Clinical Infectious Diseases. 2018; 67(10):1543–1549.

Clemessy JL, Favier C, Borron SW, Hantson PE, Vicaut E, Baud FJ. Hypokalaemia related to acute chloroquine ingestion. The Lancet. 1995; 346(8979):877–880.

Clemessy JL, Taboulet P, Hoffman JR, Hantson P, Barriot P, Bismuth C, Baud FJ. Treatment of acute chloroquine poisoning: a 5-year experience. Critical Care Medicine. 1996; 24(7):1189–1195.

577 **Gawałko M**, Balsam P, Lodziński P, Grabowski M, Krzowski B, Opolski G, Kosiuk J. Cardiac Arrhythmias in
578 Autoimmune Diseases. Circulation Journal. 2020; 84(5):685–694.

579 **Guastalegname M**, Vallone A. Could chloroquine/hydroxychloroquine be harmful in Coronavirus Disease 2019
580 (COVID-19) treatment? Clinical Infectious Diseases. 2020; .

581 **Guillon C**, Le Bonniec Y. Suicide, mode d'emploi: histoire, technique, actualité. A. Moreau; 1982.

582 **Gunja N**, Roberts D, McCoubrie D, Lamberth P, Jan A, Simes D, Hacketts P, Buckley N. Survival after massive
583 hydroxychloroquine overdose. Anaesthesia and intensive care. 2009; 37(1):130–133.

584 **Guzik TJ**, Mohiddin SA, Dimarco A, Patel V, Savvatis K, Marelli-Berg FM, Madhur MS, Tomaszewski M, Maffia
585 P, D'Acquisto F, et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis,
586 and treatment options. Cardiovascular Research. 2020; .

587 **Harris L**, Downar E, Shaikh N, Chen T. Antiarrhythmic potential of chloroquine: new use for an old drug. The
588 Canadian Journal of Cardiology. 1988; 4(6):295–300.

589 **Höglund R**, Moussavi Y, Ruengweerayut R, Cheomung A, Äbelö A, Na-Bangchang K. Population pharmacokinet-
590 ics of a three-day chloroquine treatment in patients with Plasmodium vivax infection on the Thai-Myanmar
591 border. Malaria Journal. 2016; 15(1):129.

592 **Jeevaratnam K**. Chloroquine and hydroxychloroquine for COVID-19: implications for cardiac safety. European
593 Heart Journal-Cardiovascular Pharmacotherapy. 2020; .

594 **Kang Y**, Chen T, Mui D, Ferrari V, Jagasia D, Scherrer-Crosbie M, Chen Y, Han Y. Cardiovascular manifestations
595 and treatment considerations in covid-19. Heart. 2020; .

596 **Lane JCE**, Weaver J, Kostka K, Duarte-Salles T, Abrahao MTF, Alghoul H, Alser O, Alshammari TM, Biedermann
597 P, Burn E, Casajust P, Conover M, Culhane AC, Davydov A, DuVall SL, Dymshyts D, Fernández Bertolín S,
598 Fišter K, Hardin J, Hester L, et al. Safety of hydroxychloroquine, alone and in combination with azithromycin,
599 in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case
600 series study. medRxiv. 2020; https://www.medrxiv.org/content/early/2020/05/31/2020.04.08.20054551, doi:
601 10.1101/2020.04.08.20054551.

602 **Liu J**, Cao R, Xu M, Wang X, Zhang H, Hu H, Li Y, Hu Z, Zhong W, Wang M. Hydroxychloroquine, a less toxic
603 derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discovery. 2020; 6(1):1–
604 4.

605 **Long B**, Brady WJ, Koyfman A, Gottlieb M. Cardiovascular complications in COVID-19. The American Journal of
606 Emergency Medicine. 2020; .

607 **McChesney EW**. Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate. The American Journal
608 of Medicine. 1983; 75(1):11–18.

609 **Mégarbane B**, Bloch V, Hirt D, Debray M, Résiére D, Deye N, Baud FJ. Blood concentrations are better predictors
610 of chloroquine poisoning severity than plasma concentrations: a prospective study with modeling of the
611 concentration/effect relationships. Clinical Toxicology. 2010; 48(9):904–915.

612 **Mégarbane B**, Leprince P, Deye N, Résière D, Guerrier G, Rettab S, Théodore J, Karyo S, Gandjbakhch I, Baud
613 FJ. Emergency feasibility in medical intensive care unit of extracorporeal life support for refractory cardiac
614 arrest. Intensive care medicine. 2007; 33(5):758–764.

615 **Mégarbane B**, Scherrmann JM. Hydroxychloroquine and Azithromycin to Treat Patients With COVID-19: Both
616 Friends and Foes? Journal of Clinical Pharmacology. 2020; .

617 **Monzani A**, Genoni G, Scopinaro A, Pistis G, Kozel D, Secco GG. QTc Evaluation in COVID-19 patients treated
618 with Chloroquine/Hydroxichloroquine. European Journal of Clinical Investigation. 2020; p. e13258.

619 **Multicenter collaboration group of Department of Science and Technology of Guangdong Province and**
620 **Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus**
621 **pneumonia** . Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumo-
622 nia. Zhonghua Jie He He Hu Xi Za Zhi. 2020; 43:E019.

623 **de Olano J**, Howland MA, Su MK, Hoffman RS, Biary R. Toxicokinetics of hydroxychloroquine following a massive
624 overdose. The American Journal of Emergency Medicine. 2019; 37(12):2264–e5.

625 **Pastick KA**, Okafor EC, Wang F, Lofgren SM, Skipper CP, Nicol MR, Pullen MF, Rajasingham R, McDonald EG, Lee
626 TC, Schwartz IS, Kelly LE, Lother SA, Mitjà O, Letang E, Abassi M, Boulware DR. Review: Hydroxychloroquine
627 and Chloroquine for Treatment of SARS-CoV-2 (COVID-19). Open Forum Infectious Diseases. 2020 04; 7(4).
628 https://doi.org/10.1093/ofid/ofaa130, doi: 10.1093/ofid/ofaa130, ofaa130.

629 **Pukrittayakamee S**, Tarning J, Jittamala P, Charunwatthana P, Lawpoolsri S, Lee SJ, Hanpithakpong W, Han-
630 boonkunupakarn B, Day NP, Ashley EA, et al. Pharmacokinetic interactions between primaquine and chloro-
631 quine. Antimicrobial Agents and Chemotherapy. 2014; 58(6):3354–3359.

632 **Riou B**, Barriot P, Rimailho A, Baud FJ. Treatment of severe chloroquine poisoning. New England Journal of
633 Medicine. 1988; 318(1):1–6.

634 **Saleh M**, Gabriels J, Chang D, Kim BS, Mansoor A, Mahmood E, Makker P, Ismail H, Goldner B, Willner J, et al.
635 The Effect of Chloroquine, Hydroxychloroquine and Azithromycin on the Corrected QT Interval in Patients
636 with SARS-CoV-2 Infection. Circulation: Arrhythmia and Electrophysiology. 2020; .

637 **Sapp JL**, Alqarawi W, MacIntyre CJ, Tadros R, Steinberg C, Roberts JD, Laksman Z, Healey JS, Krahn AD. Guidance
638 On Minimizing Risk of Drug-Induced Ventricular Arrhythmia During Treatment of COVID-19: A Statement
639 from the Canadian Heart Rhythm Society. Canadian Journal of Cardiology. 2020; .

640 **Savarino A**, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug
641 against today's diseases. The Lancet Infectious Diseases. 2003; 3(11):722–727.

642 **Straits Times**, Lupus patients hit by run on drug chloroquine after claims it wards against coron-
643 avirus; 2020. https://www.straitstimes.com/asia/se-asia/run-on-drug-chloroquine-despite-unproven-belief-
644 as-ward-against-coronavirus-affecting.

645 **Szekely Y**, Lichter Y, Shrkihe BA, Bruck H, Oster HS, Viskin S. Chloroquine-induced torsade de pointes
646 in a COVID-19 patient. Heart Rhythm. 2020 May; https://doi.org/10.1016/j.hrthm.2020.04.046, doi:
647 10.1016/j.hrthm.2020.04.046.

648 **Tönnesmann E**, Kandolf R, Lewalter T. Chloroquine cardiomyopathy–a review of the literature. Immunophar-
649 macology and immunotoxicology. 2013; 35(3):434–442.

650 **Vicente J**, Zusterzeel R, Johannesen L, Mason J, Sager P, Patel V, Matta MK, Li Z, Liu J, Garnett C, et al. Mecha-
651 nistic model-informed proarrhythmic risk assessment of drugs: review of the "CiPA" initiative and design of
652 a prospective clinical validation study. Clinical Pharmacology & Therapeutics. 2018; 103(1):54–66.

653 **Wang M**, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. Remdesivir and chloroquine effectively
654 inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research. 2020; 30(3):269–271.

655 **World Health Organization**. Guidelines for the treatment of malaria. World Health Organization; 2015.

656 **Wozniacka A**, Cygankiewicz I, Chudzik M, Sysa-Jędrzejowska A, Wranicz J. The cardiac safety of chloroquine
657 phosphate treatment in patients with systemic lupus erythematosus: the influence on arrhythmia, heart
658 rate variability and repolarization parameters. Lupus. 2006; 15(8):521–525.

659 **Wu JT**, Leung K, Bushman M, Kishore N, Niehus R, de Salazar PM, Cowling BJ, Lipsitch M, Leung GM. Estimating
660 clinical severity of COVID-19 from the transmission dynamics in Wuhan, China. Nature Medicine. 2020; p.
661 1–5.

662 **Yao X**, Ye F, Zhang M, Cui C, Huang B, Niu P, Liu X, Zhao L, Dong E, Song C, et al. In vitro antiviral activity and
663 projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory
664 syndrome coronavirus 2 (SARS-CoV-2). Clinical Infectious Diseases. 2020; .

Appendix 1

Appendix 1 Figure 1. Comparing the concentration fatality-curves obtained when using the retrospectively gathered data (blue dashed line, $n = 91$ *Riou et al., 1988*) versus the prospectively gathered data (black solid line, $n = 302$ *Riou et al., 1988*; *Clemessy et al., 1995, 1996*; *Mégarbane et al., 2010*). The parameters of the two logistic regression fits correspond to maximum likelihood estimates.

Appendix 2

Appendix 2 Figure 1. Comparison between prior distributions (thick red lines) and posterior distributions (shown as histograms) for the parameters of the concentration-fatality model. The top three histograms show the estimated intercept terms for the three cohorts (cohort 1: *Riou et al.* (*1988*); cohort 2: *Clemessy et al.* (*1995*, 1996); cohort 3: *Mégarbane et al.* (*2010*)). α is overall intercept term; β: log-concentration coefficient; δ: bias term for patients whose peak concentration was not observed; γ: fraction of concentration that is due to chloroquine and not the metabolite. This shows that the data are informative with respect to the β coefficient on the log concentration. This is the desired behaviour given we know that chloroquine at low doses is very safe. See the meta-analysis of the related bisquinoline compound piperaquine showing that under normal dosing, the mortality is unlikely to be greater than the background mortality rate (*Chan et al., 2018*).

Appendix 2 Figure 2. Comparison between prior distributions (thick red lines) and posterior distributions (shown as histograms) for the population parameters of the concentration-QRS duration Emax sigmoid regression model.

 ## Appendix 3

Appendix 3 Figure 1. Predicted C_{max} distributions for a 70 kg adult for the plasma pharmacokinetic model (black) and the whole blood pharmacokinetic model (red) under the 6 different regimens. The predicted plasma concentrations were scaled by 4 to produce approximate whole blood concentrations. The areas under all the curves are equal to 1, with the all y-axes given the same height in order to highlight differences in width of predicted distributions.

 Appendix 4

Appendix 4 Figure 1. Pharmacokinetic-pharmacodynamic model of chloroquine induced mortality under the plasma pharmacokinetic model of chloroquine. Top: pooled whole blood chloroquine + desethylchloroquine concentrations from admission samples in prospectively studied self-poisoning patients (*Riou et al., 1988*; *Clemessy et al., 1995*, *1996*; *Mégarbane et al., 2010*). The data are shown as overlapping histograms for survivors (blue, $n = 269$) and fatal cases (red, $n = 33$). The overlapping areas are shown by the intermediate burgundy colour. Bottom: Bayesian posterior distribution over the concentration-response curve (mean and 95% credible interval) describing the relationship between admission whole blood chloroquine concentrations (after adjustment for the deseythl metabolite) and death, with the chloroquine concentration shown on the $\log_{10}$ scale. The vertical lines show the upper 99 percentiles of the predicted C_{max} distribution in a 70 kg adult under the plasma pharmacokinetic model for the six regimens considered (yellow: 10 day regimen with maintenance dose of 310 mg; pink: 10 day regimen with maintenance dose of 600 mg; brown: 7 day regimen with maintenance dose of 310 mg; grey: malaria regimen). The vertical light pink shaded area shows the posterior credible interval over the concentrations associated with 1% mortality. This is the equivalent output of the whole blood model shown in Figure 1, main text.

Appendix 4 Figure 2. The predicted risk of fatal toxicity across the six regimens simulated under the plasma pharmacokinetic model. Panel A shows the simulated distribution of C_{max} values in a 70 kg adult for the six regimens considered. The vertical red shaded area shows the 95% credible interval for the 1% mortality threshold concentration. Panel B shows the probability that an individual will cross the 1% mortality threshold value as a function of body weight for the different regimens ($\log_{10}$ scale on the y-axis). Panel C shows the predicted mortality per thousand for the six regimens as a function of body weight.

₇₂₆ **Appendix 5**

₇₂₇
₇₂₈ **Appendix 5 Figure 1.** The total doses (in grams) and duration of 55 COVID-19 treatment trials
₇₂₉ currently recruiting participants which extracted from ClinicalTrials.gov on the 11th June 2020. The
₇₃₀ black square boxes show the four 'flat' dosing chloroquine regimens simulated in this paper. Note
₇₃₁ that multiple trials give the exact same dose regimen so there are fewer than 55 unique points on the
₇₃₂ graph. Some multi-country trials such as SOLIDARITY use both hydroxychloroquine or chloroquine
₇₃₃ depending on the countries included. As the majority of countries worldwide use hydroxychloroquine
₇₃₅ we have coloured these trials in red. The extracted data can be found in the supplementary materials.

736 Appendix 6

737
738 **Appendix 6 Figure 1.** Raw concentration-QRS scatter plot without any bias adjustment or truncation
739 for the QRS data. To model the relationship between concentrations and QRS we truncated the QRS
740 values at 200 msec (durations longer than 200 msec are physiologically very unlikely) and estimated a
742 bias term for the data from the Clemessy series (*Clemessy et al., 1995*, *1996*).

743 **Appendix 7**

744
745 **Appendix 7 Figure 1.** Electrocardiograph showing marked intraventricular conduction delay (QRS
746 widening) with moderate JT prolongation in a 28 year old female who had taken 5 g of chloroquine.
747 Her admission whole blood chloroquine + desethychloroquine concentration was 35.4 μmol/L but
749 fortunately she survived. .